Lung cancer is no. 3 of death causes in Germany. Only heart attacks and strokes kill more people (data from 2010). Treatment options have already improved in the last ten years: Today, lung cancer can be characterized in a more detailed way – and patients can be treated more individually. Nevertheless there is a strong need for intensive research in the areas of diagnosis and therapy.
Focus in ARCN:
ARCN is working mainly on non-small cell lung cancer (NSCLC). By comparing diseased and healthy tissue with molecular techniques, we aim to find differences that explain higher risks rates. These results might lead to improved early diagnosis. We also want to find biomarkers that predict the prognosis of the disease.